Uncertainty around tariffs and macroeconomic conditions has dented investor confidence, resulting in stock prices falling. While some stocks have come under pressure due to the above two reasons, others have simply followed the market direction or have dipped for company-specific reasons.
Regardless of the reasons for stocks going down, falling stocks provide an opportunity for fresh investors to get in at good prices. Once the risks subside, these stocks usually recover quickly as well. We decided to uncover these stocks and see if it makes sense to put money in them to take advantage of the ongoing market turmoil.
To come up with our list of top 20 stocks falling with unusual volume, we looked at stocks over $300 million in market cap, their one-week performance, and used relative volume to detect the unusual volume activity.
Relative volume compares the daily volume to the three-month average trading volume of the stock, making it easy to detect spikes in volume. These spikes usually signal something important is happening, which, when combined with falling prices, becomes a red flag that investors can’t ignore.
20. Elevance Health, Inc. (NYSE:ELV)
Elevance Health, Inc. is a health benefits company. The company operates through Health Benefits, Carelon Services, CarelonRx, and Corporate & Other segments. It provides a variety of health services and plans to Medicare, individual, FEP, Medicaid, employer group risk-based and fee-based, and BlueCard members. The company’s stock is down 2.71% on a relative volume of 2.09.
The reason for this lackluster performance is a policy risk related to Medicaid. Recently, Baird’s analyst Michael Ha downgraded the stock from Outperform to Neutral. The firm also adjusted its price target downward from $625 to $529.
Following the state Gov. Sarah Huckabee Sanders’ signing a law banning pharmacy benefit managers (PBMs) from operating or owning pharmacies, ELV announced plans to close over 20 pharmacies in Arkansas. This has spooked some investors, but things aren’t as bad as they look for the company.
Elevance provided a stable full-year outlook at its recent earnings. As per the guidance, it expects its Medicare Advantage membership to hit somewhere between 2.2 million and 2.25 million members in 2025. Its projected full-year non-GAAP EPS is $34.5 at the midpoint with a non-GAAP net income of $11.97/share for Q1 2025. The stock continues to face pressure regardless of the positive outlook, but that’s precisely what makes it a good buying opportunity.
19. Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
Zimmer Biomet Holdings, Inc. is a medical technology company. It manufactures, markets, and designs orthopedic reconstructive products. The company provides bone cement, technology and data, and surgical products. It serves neurosurgeons, stocking distributors, orthopedic surgeons, healthcare dealers, hospitals, and other specialists.
The medical firm’s stock is down 4.24% in a week on a relative volume of 2.14. The stock has been tumbling since the start of the month due to tariff fears, but the market seems to have overreacted. Earlier this week, Barclays pointed out ZBH as one of the least affected stocks from Trump’s tariffs. News on other fronts has also been positive.
The U.S. FDA cleared the company’s Persona Revision SoluTion Femur last month. This is a new knee implant component designed for patients with metal sensitivities. According to ZBH, Persona Revision SoluTion Femur is anticipated to launch in the U.S. in Q3 2025.
The firm’s president, Joe Urban, mentioned:
“We are pleased to expand our proprietary surface-hardening technology into the revision knee space with FDA clearance of the Persona Revision SoluTion Femur, the first metal alternative option for those with certain metal sensitivities.”
Based on the company’s provided outlook, it plans to introduce over 50 new products in the next 3 years. Anticipated constant currency revenue growth is in the range of 3% to 5%. Management predicts an improved margin and revenue in the latter half of the year. This growth trajectory is expected to be well complemented by operational improvements and new product ramp-ups, making the current dip attractive.
Hedge Fund Resource Center